Acromegaly market seen reaching $5.84 billion by 2030
The global acromegaly treatment market is projected to grow from $2.56 billion in 2025 to $5.84 billion by 2030, driven by more awareness, better diagnosis and expanding treatment options. North America led the market in 2025, while digital health, precision medicine and outpatient care are expected to shape future growth.
Why it matters: - The acromegaly market is expanding as rare-disease diagnosis improves and treatment access widens. - The projected jump to $5.84 billion by 2030 signals stronger demand for therapies, monitoring tools and care models that can support earlier intervention. - The market’s growth also reflects rising attention to hormonal disorders that often overlap with conditions such as diabetes.
What happened: - The Business Research Company said the acromegaly market is expected to grow from $2.56 billion in 2025 to $3.01 billion in 2026. - The company projected a compound annual growth rate of 17.5% from 2025 to 2026. - The market is forecast to reach $5.84 billion by 2030, with an 18.1% CAGR through the period. - The report was released Oct. 28, 2026, and includes regional coverage across North America, Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the report. - View the full acromegaly market report.
The details: - Limited diagnostic tools and a rising prevalence of growth hormone disorders are key drivers behind market growth. - Hospital infrastructure and specialty clinics have improved access to diagnosis and treatment. - Traditional treatment methods remain in use alongside broader awareness of rare endocrine conditions. - Advanced somatostatin analogues and more available parenteral therapies are expected to support future demand. - Precision medicine strategies are becoming more important in acromegaly care. - Outpatient and homecare treatment models are gaining traction. - Digital health technologies and remote monitoring tools are improving patient management and outcomes. - Acromegaly is a rare endocrine disorder caused by excess growth hormone from the pituitary gland. - The hormone excess leads to abnormal enlargement and thickening of bones and tissues, especially in the hands, feet and face. - If untreated, acromegaly can cause significant physical changes and health complications. - About half of acromegaly patients develop insulin resistance or type 2 diabetes because elevated growth hormone affects insulin production. - North America was the leading region for the acromegaly market in 2025.
Between the lines: - The market story is not just about more patients. It is also about better detection of a condition that has historically been underdiagnosed. - The emphasis on digital monitoring and outpatient care suggests a shift toward long-term disease management outside traditional hospital settings. - The report’s focus on diabetes underscores how acromegaly growth is tied to broader endocrine care trends, not a single therapy class. - The Business Research Company said the 2026 edition of its market reports includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated trend analysis.
What's next: - Market growth is likely to depend on how quickly advanced therapies reach broader use and how well health systems expand early diagnosis. - Adoption of precision medicine and remote monitoring could reshape how acromegaly is treated over the next several years. - Regional performance will likely continue to vary, with North America leading and other markets catching up as access improves.
The bottom line: - The acromegaly market is on a steep growth path, driven by better awareness, evolving treatment options and a shift toward more personalized care.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Health Times of Africa
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.